The Global Health Body Raises Alert Over Critical Scarcity of Weight-Loss Jabs

Under a tenth of individuals eligible to benefit from GLP-1 drugs like Wegovy can access them, caution the World Health Organization as it issues its initial recommendations on the therapies.

With in excess of 1,000,000,000 individuals worldwide now classified as obese, it is urging broader and more equitable access to these injectable treatments.

According to forecasts, in excess of 2,000,000,000 could be obese by 2030 without intervention.

"The latest guidelines recognises that excess weight is a chronic disease that can be managed with thorough and ongoing support," said the agency's head Tedros Adhanom Ghebreyesus.

Significant expense, constrained manufacturing, and logistical bottlenecks are significant barriers to broad availability to the treatments that can aid individuals in losing substantial body mass, explains the body.

GLP-1 Therapy Supply Crisis

Despite the current most optimistic outlook, the supply of these medications might only reach around 100 million people – fewer than 10% of eligible patients, per the WHO.

The advice encourages countries and companies to widen availability, through measures like voluntary licensing.

The intellectual property rights on semaglutide – the core component of a leading brand – is scheduled to end in multiple nations in 2026.

The Way Obesity Jabs Operate

These medications mimick a natural hormone to reduce digestion speed, suppress the appetite and boost satiety so users eat less.

Individuals usually start to lose weight within a few weeks of beginning the regular doses.

Evidence points to users may regain a significant portion a year later of discontinuing the drug, as their usual food cravings resume.

Being above a healthy weight raises your likelihood for developing medical conditions, such as diabetes, cardiovascular issues, stroke, and specific malignancies.

Obesity affects individuals in every country and was responsible for 3.7 million deaths worldwide in 2024, according to the health agency.